Drug intelligence / Profile preview

9-(4-hydroxyphenyl)-2,7-phenanthroline

Development stage: Unknown
Modality: Small Molecules

Overview

9-(4-hydroxyphenyl)-2,7-phenanthroline is a synthetic small molecule belonging to the class of phenanthrolines. Structurally, it consists of a 2,7-substituted phenanthroline core with a para-hydroxyphenyl group at position 9. It has been identified as an inhibitor of mitogen-activated protein kinase (MAPK), specifically mitogen-activated protein kinase 10 (also known as JNK3). The compound is primarily used in research settings and has not been approved for clinical use or marketed as a pharmaceutical product[1][3][5]. Its main application is experimental inhibition of MAPK pathways in biochemical and structural studies.

Other names: 4-(2,7-phenanthrolin-9-yl)phenol

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on 9-(4-hydroxyphenyl)-2,7-phenanthroline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9-(4-hydroxyphenyl)-2,7-phenanthroline.

Explore the full profile